Universal Health Services UHS
Universal Health Services operates acute care hospitals and behavioral health centers in the United States, generating revenue from medical and hospitalization services. UHS trades at a P/E of 7.30 and EV/EBITDA of 5.86, reflecting an attractive valuation, supported by a 20.95% ROE and 10.1% earnings growth, although free cash flow conversion is weak (18.46%).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Universal Health Services operates acute care hospitals and behavioral health centers in the United States, generating revenue from medical and hospitalization services. UHS trades at a P/E of 7.30 and EV/EBITDA of 5.86, reflecting an attractive valuation, supported by a 20.95% ROE and 10.1% earnings growth, although free cash flow conversion is weak (18.46%).
Score by category
| Category | Score |
|---|---|
| Financial health | 5.8 |
| Quality / Moat | 6.0 |
| Valuation | 7.9 |
| Growth | 6.3 |
| Dividend | 2.4 |
| Momentum | 2.9 |
| Risk & Context | 6.0 |
OVERALL SCORE: 5.9/10
Context and risks
No direct exposure to interest rates, commodities, or geopolitical tensions that materially affect UHS's hospital business. The macro context has no specific impact on this company.
News considered in the analysis
- Can Tenet Healthcare Sustain Growth Despite Lower Surgical Volumes? — Artículo de análisis sobre un competidor (Tenet), sin información nueva sobre UHS.
- Universal Health Services Stock: Is UHS Underperforming the Health Care Sector? — Comparativa de rendimiento sectorial sin datos concretos que afecten a la valoración de UHS.
- How Acadia Healthcare Is Turning Capacity Growth Into Cash Flow — Análisis de un competidor (Acadia), sin implicaciones directas para UHS.
- CVS Still Sees 'High-Trend' Cost Growth; Oscar, UNH Stock Fall — Noticia sobre costes en el sector asegurador (CVS, UNH), no aplica directamente al negocio de hospitales de UHS.
- Can Operational Resiliency Protect HCA's Long-Term Profitability? — Análisis de un competidor (HCA), sin información relevante para UHS.
Verdict: Hold; the valuation is attractive but weak free cash flow conversion and poor momentum (score 2.89) limit near-term upside.
Main risk: Low free cash flow conversion (18.46%) may indicate collection issues or high capital expenditures that could limit the ability to create shareholder value.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →